What patent covers trilaciclib (and what does it protect)?
Trilaciclib (marketed as COSELA) is protected by multiple patent families that can cover different aspects of the product, such as the active ingredient and its formulation, methods of preparation, and specific clinical uses (for example, dosing in connection with chemotherapy). Patent coverage for a given drug is rarely a single patent; it is usually a layered set of patents whose remaining life depends on the jurisdiction and filing dates.
How do I find the exact trilaciclib (Trilaciclib spiro) patent number?
The fastest way is to search patent databases using combinations of:
- “trilaciclib” and “spiro”
- the company/applicant name associated with COSELA in each country (commonly the original innovator and its affiliates)
- related chemical or code names for trilaciclib used in patent documents
Patent records typically list an application number, publication number, and one or more granted claims, which is what you’d use to identify the specific “Trilaciclib spiro” patent(s).
When does trilaciclib’s patent protection expire?
Patent expiration depends on:
- the jurisdiction (US, EP, JP, etc.)
- whether patents were granted and then expire based on their filing/patent term rules
- whether patent term extensions or supplementary protection certificates apply (common in Europe)
- any exclusivity not tied to a patent (regulatory exclusivity can extend market protection beyond a patent term)
Because trilaciclib has multiple patent families, different patents will expire at different times, so the relevant date for “can competitors enter” depends on which patent(s) a challenger is targeting.
Are there biosimilar-style challenges or generic competition?
For small-molecule oncology drugs like trilaciclib, competition typically comes through generic pathways and patent challenges rather than biosimilar mechanisms. Companies may challenge specific patents listed in regulatory patent registries (in the US, for example, the Orange Book) to clear the way for earlier approval of generic versions once those patents are no longer enforceable or no longer block approval.
How can I tell which patent is the “important” one for competition?
Look for patents that:
- are listed for the approved drug in the relevant regulatory patent listing for each country, and
- have remaining enforceable term (not expired) and valid, asserted claims.
Those are the patents that tend to drive timing for generic/atypical entry rather than patents that are already expired or not listed.
If you share details, I can pinpoint the exact “Trilaciclib spiro” patent
If you tell me any one of the following, I can help identify the specific patent(s) you mean:
- the country (US, Europe, UK, etc.)
- the applicant/assignee name you’re seeing
- the patent number you have (even partial), or a link you found
- the exact wording you’re using (“trilaciclib spiro” plus any additional terms from the document)